Theravance Biopharma Inc TBPH:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 4:00 PM EDT15.92UNCH (UNCH)
Volume
4,677
Close
15.92
+0.34 (+2.18%)
+0.34 (+2.18%)Volume
330,074
52 week range
10.42 - 21.03
- Open15.65
- Day High16.18
- Day Low15.65
- Prev Close15.58
- 52 Week High21.03
- 52 Week High Date01/22/26
- 52 Week Low10.42
- 52 Week Low Date06/17/25
Latest On Theravance Biopharma Inc
Key Stats
- Market Cap820.724M
- Shares Out51.55M
- 10 Day Average Volume0.42M
- Dividend-
- Dividend Yield-
- Beta0.18
Latest On Theravance Biopharma Inc
KEY STATS
- Open15.65
- Day High16.18
- Day Low15.65
- Prev Close15.58
- 52 Week High21.03
- 52 Week High Date01/22/26
- 52 Week Low10.42
- 52 Week Low Date06/17/25
- Market Cap820.724M
- Shares Out51.55M
- 10 Day Average Volume0.42M
- Dividend-
- Dividend Yield-
- Beta0.18
RATIOS/PROFITABILITY
- EPS (TTM)2.20
- P/E (TTM)7.22
- Fwd P/E (NTM)8.25
- EBITDA (TTM)6.575M
- ROE (TTM)50.17%
- Revenue (TTM)109.775M
- Gross Margin (TTM)31.69%
- Net Margin (TTM)104.34%
- Debt To Equity (MRQ)11.29%
EVENTS
- Earnings Date08/10/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MORETheravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease...
Susannah Gray
Independent Chairman of the Board
Rick Winningham
Chief Executive Officer, Director
Aziz Sawaf
Chief Financial Officer, Senior Vice President
Address
UGLAND HOUSE, SOUTH CHURCH STREET
George Town
KY1-1104
Cayman Islands